In the theory of traditional Chinese medicine (TCM),
“liver-qi”
stagnation and heat-induced toxicity represent the main etiologies
of breast cancer. Recently, several TCMs with heat-clearing and detoxification
efficacy have shown inhibitory effects on breast cancer. Jin’gan
capsules (JGCs), initially approved to treat colds in China, are a
heat-clearing and detoxification TCM formula. However, the anticancer
activity of JGCs against breast cancer and its underlying mechanisms
remain unclear. First, we assessed the antiproliferative activity
of JGCs in breast cancer cell lines and evaluated their effects on
cell apoptosis and the cell cycle by flow cytometry. Furthermore,
we identified the potential bioactive components of JGCs and their
corresponding target genes and constructed a bioactive compound–target
interaction network by ultra-performance liquid chromatography–high-resolution
tandem mass spectrometry (UPLC-HR-MS/MS) and network pharmacology
analysis. Finally, the underlying mechanism was investigated through
gene function enrichment analysis and experimental validation. We
found that JGCs significantly inhibited breast cancer cell growth
with IC
50
values of 0.56 ± 0.03, 0.16 ± 0.03,
and 0.94 ± 0.09 mg/mL for MDA-MB-231, MDA-MB-468, and MCF-7,
respectively. In addition, JGC treatment dramatically induced apoptosis
and S phase cell cycle arrest in breast cancer cells. Western blot
analysis confirmed that JGCs could regulate the protein levels of
apoptosis- and cell cycle-related genes. Utilizing UPLC-HR-MS/MS analysis
and network pharmacology, we identified 7 potential bioactive ingredients
in JGCs and 116 antibreast cancer targets. Functional enrichment analysis
indicated that the antitumor effects of JGCs were strongly associated
with apoptosis and the Janus kinase (JAK)-signal transducer and activator
of transcription (STAT) signaling pathway. Western blot analysis validated
that JGC treatment markedly decreased the expression levels of
p
-JAK2,
p
-STAT3, and STAT3. Our findings
suggest that JGCs suppress breast cancer cell proliferation and induce
cell cycle arrest and apoptosis partly by inhibiting the JAK2/STAT3
signaling pathway, highlighting JGCs as a potential therapeutic candidate
against breast cancer.